Controversies in Upfront Consolidations with High Dose Therapy and Stem Cell Transplant: Poor Risk DLBCL and MCL
This information was originally presented on September 14, 2012, at the NCCN 7th Annual Congress: Hematologic Malignancies™ held in New York, New York.
This activity is designed to meet the educational needs of hematologists, oncologists, nurses, pharmacists, and other health care professionals who manage patients with hematologic malignancies.
Following this activity, participants should be able to:
- Discuss the current approaches to treatment of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL), including post-remission consolidation or maintenance strategies
- Identify patients with DLBCL or MCL who are suitable candidates for post-remission treatment approaches
Jeremy S. Abramson, MD
Massachusetts General Hospital Cancer Center
- 0.50 Participation
- 0.62 Nurse
- 0.50 Pharmacist
- 0.50 Physician